{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T01:45:10Z","timestamp":1774921510447,"version":"3.50.1"},"reference-count":0,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[1993,12,1]],"date-time":"1993-12-01T00:00:00Z","timestamp":754704000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hybridoma"],"published-print":{"date-parts":[[1993,12]]},"abstract":"<jats:p>\n                    We have generated a murine monoclonal antibody (UV3) which recognizes an epitope on ICAM-1 expressed on myeloma cells. By flow cytometric analysis, the epitope on ICAM-1 recognized by this antibody is strongly expressed on human myeloma cells, pre-B leukemia cells and Burkitt's lymphoma cell lines. Most human T cell lines are weakly positive. The antibody does not react with red blood cells, polymorphonuclear leukocytes (PMNs) or resting B lymphocytes from normal donors, and reacts very weakly with resting T cells. Immunohistochemical assays indicate that the antibody does not react with normal liver, kidney, heart, brain, thymus or lung. An immunotoxin (IT) was prepared by coupling UV3 to deglycosylated ricin A-chain (dgA). In protein synthesis inhibition assays it was highly cytotoxic to the human myeloma cell lines HS-SULTAN (IC\n                    <jats:sub>50<\/jats:sub>\n                    = 1 X 10\n                    <jats:sup>-11<\/jats:sup>\n                    M) and ARH-77 (IC\n                    <jats:sub>50<\/jats:sub>\n                    = 9 x 10\n                    <jats:sup>-11<\/jats:sup>\n                    M), but not to cell lines of T cell lineage or most cell lines of the B lineage. Our results suggest that the UV3-dgA may have therapeutic potential for the treatment of human multiple myeloma.\n                  <\/jats:p>","DOI":"10.1089\/hyb.1993.12.661","type":"journal-article","created":{"date-parts":[[2009,5,25]],"date-time":"2009-05-25T12:44:26Z","timestamp":1243255466000},"page":"661-675","source":"Crossref","is-referenced-by-count":12,"title":["Cytotoxicity of a Novel Anti-ICAM-1 Immunotoxin on Human Myeloma Cell Lines"],"prefix":"10.1177","volume":"12","author":[{"given":"Yi-Wu","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis J.","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen S.","family":"Vitetta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,4,24]]},"container-title":["Hybridoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hyb.1993.12.661","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hyb.1993.12.661","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:48:02Z","timestamp":1774918082000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hyb.1993.12.661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993,12]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1993,12]]}},"alternative-id":["10.1089\/hyb.1993.12.661"],"URL":"https:\/\/doi.org\/10.1089\/hyb.1993.12.661","relation":{},"ISSN":["0272-457X"],"issn-type":[{"value":"0272-457X","type":"print"}],"subject":[],"published":{"date-parts":[[1993,12]]}}}